 BMO Capital Markets initiated coverage on Legend Biotech Corporation NASDAQ: LEGN with a price target of 77, and an Outperform rating. The analyst says the companys recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. 